Source: International Congress 2019 – Imaging in respiratory disease: novel technologies in 2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Topole (Parma, Italy), O. Usmani (London, United Kingdom), B. Mignot (Kontich, Belgium), D. Belmans (Kontich, Belgium), C. Van Holsbeke (Kontich, Belgium), J. De Backer (Kontich, Belgium), R. Osello (Parma, Italy), E. Cuoghi (Parma, Italy), G. Georges (Parma, Italy), N. Scichilone (Palermo, Italy). Lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using Functional Respiratory Imaging (FRI).. 3167

Member's Comments

No comment yet.

Related content which might interest you: Lung deposition of extrafine inhaled corticosteroid (ICS)-containing fixed combinations drug in COPD patients using Functional Respiratory Imaging (FRI). Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018 Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI). Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019 Evaluation of inhalant deposition of ICS/LABA in the peripheral airway of asthma patients using Functional Respiratory Imaging (FRI) Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Lung deposition of two bronchodilators in subjects with (COPD) when administered via standard jet nebulizer or Handihaler® using functional respiratory imaging (FRI). Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020 Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Effects of combining tiotropium and salmeterol/fluticasone propionate on airway dimensions in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Z7200 versus Symbicort® Turbohaler®: A pharmacodynamic evaluation of the acute effects using functional respiratory imaging (FRI) Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD Source: International Congress 2014 – Asthma and COPD management Year: 2014 Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Evaluation of IL-8 and MEF25-75 in patients with severe COPD who were treated with combined therapy of ICSs / LABAs plus tiotropium bromide Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Evaluation of airway sGaw in Japanese COPD patients treated with triple therapy using salmeterol/fluticasone propionate 50/250 and tiotropium bromide Source: International Congress 2015 – COPD: interesting notes Year: 2015 Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effects of inhaled salmeterol/fluticasone on lung function in patients with bronchiectasis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014